Summary We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this combination. Fourteen previously untreated patients with stage IIIB or IV disease were treated with CPT-11 (90-min intravenous infusion on days 1, 8, and 15) plus cisplatin (60 mg m2, intravenously on day 1). The starting dose of CPT-11 was 60 mg m-2, and diarrhea was the dose-limiting toxicity at the 90 mg m-2 dose level. All three patients (all four cycles) given 90 mg m'2 of CPT-11 experienced grade 3 diarrhea.
Cisplatin is one of the most widely used anticancer agents, and is an essential component of potentially curative regimens for testicular cancer, ovarian cancer, bladder cancer, and small cell lung cancer (SCLC) . In addition, cisplatin is among the most active single agents for head and neck cancer, non-small cell lung cancer (NSCLC), and endometrial cancer (Chabner & Myers, 1989) .
Irinotecan (CPT-11) is one of a series of semisynthetic camptothecin derivatives that was produced in an attempt to reduce the toxicity and improve the therapeutic efficacy of the parent compound by increasing its water solubility without opening the lactone ring. CPT-11 inhibits topoisomerase I activity through the formation of stable topoisomerase I-DNA cleavable complexes (Hsiang et al., 1985; Hsiang & Liu, 1988; Hertzberg et al., 1989) . It has a strong antitumour activity in a broad spectrum of experimental tumour models (Kunimoto et al., 1987; Matsuzaki et al., 1988) , and is also active against leukaemia, lymphoma (Ohno et al., 1990) , and several common solid tumours in humans (Negoro et al., 1991b; Shimada et al., 1991; Takeuchi et al., 1991; Fukuoka et al., 1992; Masuda et al., 1992a) .
Because enhancement of in vitro and in vivo antitumour activity was observed when CPT-11 was combined with cisplatin in preclinical studies (Takada et al., 1992) , we performed a Phase I trial of escalating doses of CPT-l 1 on days 1, 8, and 15 combined with 80 mg m-2 of cisplatin on day 1 (cycles repeated at 4-week intervals) in patients with advanced NSCLC (Masuda et al., 1992b) . A very promising response rate of 54% was obtained. The maximum tolerated dose of CPT-1 1 was 70mg m2, with the dose-limiting toxicities being leukopenia and diarrhea. However, CPT-1 1 could be safely administered at only 45% (60 mg m-2 on days 1, 8, and 15) of the dose intensity achieved when it was used as a single agent (100 mg m-2 per week) (Negoro et al., 1991a) . Combining these two drugs may produce considerably more bone marrow toxicity than is seen with either drug alone, and the optimal dosage and scheduling for combination chemotherapy have yet to be defined. In the present study, we reduced the cisplatin dose from 80 mg m-2 to 60 mgM-2 and increased the dose of in an attempt to maximise the potential of this drug for achieving a cytocidal effect. The objectives of this Phase I study were: (i) to determine the maximum tolerated dose of CPT-1 1 in combination with a fixed dose of 60 mg m-2 of cisplatin; (ii) to detect and quantify the clinical toxicities of this combination; (iii) to determine the pharmacokinetics of CPT-l 1 and its major metabolite (7-ethyl-10-hydroxycamptothecin; , and to evaluate whether there was relationship between the pharmacokinetic parameters and clinical toxicity; and (iv) to obtain preliminary data on the therapeutic activity of this combination in patients with advanced lung cancer.
Patients and methods

Patient selection
Prior to enrollment in the study, lung cancer patients admitted to the Osaka Prefectural Habikino Hospital were examined to make sure they met the following criteria: (i) a histologic diagnosis of lung cancer; (ii) stage IIIB or IV disease; (iii) no prior chemotherapy or radiotherapy; (iv) life expectancy of at least 12 weeks; (v) age < 75 years; (vi) performance status of 2 or better on the Eastern Cooperative Oncology Group (ECOG) scale; (vii) adequate bone marrow function (leukocyte count > 4,000 tIl-, platelet count >,100,000 yII-', and hemoglobin , 9 g dl-'), adequate hepatic function (bilirubin < 1.5 mg dl-', transaminases < twice the upper limit of normal), and adequate renal function (creatinine < 1.4 mg dl-', 24-h creatinine clearance > 60 ml min-'); (viii) no concurrent active malignancy; and (ix) no medical problems severe enough to prevent compliance with the protocol. All subjects gave written informed consent to the study. Patients were not eligible if they showed an allergic response to a prick skin test with CPT-1 1. The study was approved in advance by this hospital's Institutional Review Board.
Dose escalation procedure
The dose of cisplatin was fixed at 60 mgM-2 intravenously on day 1. The starting dose of CPT-11 was 60 mg m-2 intravenously on days 1, 8, and 15, which was the recommended dose for use with 80 mg m-2 of cisplatin on the basis of the previous phase I study (Masuda et al., 1992b) . Thereafter, new patients received CPT-l 1 at 80 mg m-2 and then the dose was planned to be increased at increments of 10 mg m2 in successive patient cohorts (Table I) . At least three patients were included in each dose level, and the regimen was repeated every 28 days. (Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan and Yakult Honsha Co. Ltd., Tokyo, Japan) was dissolved in 500 ml of normal saline and given as a 90-min intravenous infusion. Cisplatin was given intravenously over 90 min at 2 h after CPT-1 1 administration as described previously (Masuda et al., 1992b (World Health Organization, 1979) . The duration of each response was defined as the number of days from the documentation of response until tumour progression. ECOG common toxicity criteria were used to grade organ damage. The maximum tolerated dose was defined as the dose causing grade 3-4 nonhematologic toxicity (except nausea and vomiting) in at least one-third of the cycles and/or grade 3-4 hematologic toxicity in at least two-third of the cycles included at that level.
Pharmacokinetics Heparinised blood samples (2 ml) for the pharmacokinetic study were obtained before infusion of at (Tables III and IV) .
Leukopenia was the most common hematologic side effect, but none of the patients exhibited grade 4 leukopenia. Grade 3 leukopenia occurred in five patients during six cycles, and it, respectively, occurred in 33%, 15%, and 0% of the courses involving 60, 80, and 90mgm-2 doses. Thus, it did not seem to be a dose-related phenomenon. This may have partly been due to our dose modification procedure, in which CPT-11 was ceased if the leukocyte count was <3,000fil-l when treatment was due. The leukocyte nadir usually occurred around day 21, with recovery in most patients by day 29.
Little cumulative toxicity was detected in the subsequent courses at any dose level. Transient eosinophilia ( > 10%) was observed in seven (21 %) courses. Other types of hematologic toxicity were of minor importance (Table IV) . There were negligible effects on the platelet count in this trial and no grade 2 or worse thrombocytopenia was observed in all 33 courses. Grade 3 anaemia was observed on only two (6%) occasions in 33 courses. In almost all of the patients, sufficient recovery from myelosuppression had occurred by day 29, allowing a repeat course to be commenced after 28 days. creased with increasing doses of CPT-1 . A rapid increase in the plasma concentration of SN-38, which was the only°m etabolite detected, was observed in the first 30 min ( Figure  2 ). The plasma SN-38 concentration decreased more slowly than that of CPT-1 1, with a mean terminal half-life of o 22.31 ± 13.28 (s.d.) ng ml'. In sharp contrast to the results x+ reported for single agent administration as a weekly intra-+1+1 I venous infusion (Negoro et al., 1991a) CPT-l 1 in this phase I study (Table VI) 
Discussion
Preclinical studies demonstrated that CPT-11 and its major active metabolite (SN-38) may be synergistic with cisplatin (Takada et al., 1992) . The starting dose of CPT-11 for the present study was chosen on the basis of the results of a previous phase I trial in patients with advanced NSCLC at our institution (Masuda et al., 1992b) . The recommended dose of CPT-1 1 in combination with 80 mg m-2 of cisplatin was found to be 60 mgm2, with leukopenia and diarrhea being the dose-limiting toxicities. The dose intensity of CPT-11 achieved with this schedule was only 45% of that reported for a single-agent administration as a weekly intravenous infusion Negoro et al., 1991a) , showing that the combined administration of full doses of both these drugs was not feasible. In view of the high single-agent activity of CPT-11 against SCLC (Negoro et al., 1991b; Masuda et al., 1992a) and NSCLC , a regimen with a higher dose of this agent and a lower dose of cisplatin seemed likely to be more active. The dose-limiting toxic effect of this combination was severe diarrhea and myelosuppression was not a dose-limiting problem in this trial (Table III) . Because all three patients given 90 mg m-2 of CPT-11 developed grade 3 diarrhea during their first course of therapy, we stopped further dose escalation of this agent. Therefore, a dose of 80 mg m-2 of CPT-1 1 given intravenously on days 1, 8, and 15 plus 60 mg m-2 of cisplatin every 4 weeks is the recommended starting dose for future Phase II studies in patients who have had no prior chemotherapy. Reduction of the cisplatin dose to 60 mg m-2 (a 25% decrease in the cisplatin dose intensity) allowed in the safe administration of CPT-1 1 at 80 mg m-2 without dose-limiting diarrhea or leukopenia and resulted in a 33.3% dose intensification of the latter agent compared with the previous Phase I trial.
Although marked interpatient variability of gastrointestinal toxicity was observed in this study, which is a well known feature of CPT-11 (Negoro et al., 199 la; Negoro et al., 1991b; Fukuoka et al., 1992; Masuda et al., 1992a) , it seems likely that development of diarrhea was related to the pharmacokinetic behavior of SN-38 as reported by Sasaki et al. (Sasaki et al., 1992) , especially to the Cmax of SN-38 in this trial. The abrupt increase in the frequency of diarrhea observed on this trial with the modest increase in the CPT-1 1 dose from 80 mg m-2 to 90 mg m-2 may be explained by the marked increase of this metabolite. In our previous phase I study for single agent administration as a weekly infusion (Negoro et al., 199 la) , the AUC values of CPT-11 were 2.97, 6.37, 9.17, and 11.29 ytg ml-' x hours after administration of 50, 100, 125, and 150 mg m-2 of CPT-1 1, respectively, showing a nonlinear pharmacokinetics of CPT-1 1. The AUC values of SN-38 increased from 117 to 252 ng ml-' x hours with a dose intensification of CPT-11 from 50 to 125 mg m-2. The AUC values of SN-38 tended to increase with the increase of the CPT-11 dose in that trial although there was wide variability in each patient. Therefore, the extraordinary increase in the plasma SN-38 levels with the slight increase in the CPT-1 1 dose in this trial was an unexpected event. These results strongly suggest the pharmacokinetic interaction between CPT-11 and cisplatin although the precise mechanism of this unexpected increase in SN-38 remains to be elucidated. In any case, if SN-38 plays an essential role in the onset of diarrhea, the activity of carboxylesterase (which catalyses the transformation of CPT-1 1 to SN-38) may be an important determinant of toxicity. Carboxylesterase shows different levels of expression in different species and different organs. In contrast with rats (Tsuji et al., 1991) , metabolism in human plasma is unlikely to contribute to the formation of SN-38, so metabolism in the liver and gastrointestinal tract epithelium may play a predominant role in the toxicity of CPT-11. If so, the prediction of which patients will experience severe toxicity is likely to be difficult, because we do not have any way to determine the enzyme activity in the liver or gastrointestinal tract. Sandostatin was reported to be effective for the diarrhea due to chemotherapy or radiotherapy (Kennedy et al., 1990; Petrelli et al., 1992) , but the severe diarrhea observed in this trial did not respond to subcutaneous sandostatin in all of three patients treated. This may reflect a difference in the mechanism of diarrhea caused by a combination of CPT-11 and cisplatin and that seen as a complication of pelvic radiotherapy or of chemotherapy with 5-fluorouracil. Since sandostatin was ineffective in reducing diarrhea, the use of high-dose loperamide or more potent anti-diarrheal agents should be investigated to control severe diarrhea induced by this protocol. In addition, further studies to elucidate the precise mechanisms by which CPT-11 causes diarrhea are needed.
In summary, this study has shown that CPT-1 1 can be given at 80% of the recommended single-agent dose in combination with 60 mg m-2 of cisplatin, while achieving acceptable toxicity. The major dose-limiting toxicity of this combination was diarrhea. In this Phase I study of 14 patients with advanced lung cancer, we observed five (36%) partial responses and one (7%) complete response, for an overall response rate of 43%. For future phase II studies, the recommended doses are 80 mg m-2 of CPT-11 (days 1, 8, and 15) plus 60 mg m-2 of cisplatin (day 1) at 4-week intervals. A Phase II trial of this regimen in previously untreated SCLC patients would be appropriate.
